Skip to main content
SpringerLink
Log in

Vortioxetine: A Review of Its Use in Major Depressive Disorder

  • Adis Drug Evaluation
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Vortioxetine (Brintellix®) is a serotonin (5-HT) transporter inhibitor that also acts on several 5-HT receptors, such as the 5-HT3 and 5-HT1A receptors. It is approved in the US and the EU for the treatment of adult patients with major depressive disorder (MDD); this article reviews the pharmacological properties of oral vortioxetine and its clinical efficacy and tolerability in these patients. Vortioxetine is generally efficacious in patients with MDD in acute treatment trials (including elderly patients), in a relapse-prevention trial, and in open-label extension trials. It is associated with improved cognitive function in patients with MDD; this does not occur solely via improvement in depressive symptom severity. It is well tolerated, but is associated with significantly increased sexual dysfunction at the highest dosage; however, vortioxetine was shown to improve previous-treatment-emergent sexual dysfunction in patients with well-treated MDD to a greater degree than escitalopram. Vortioxetine extends the available treatment options for patients with MDD, and further investigation into its comparative efficacy versus other antidepressants will allow for more accurate placement among these treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American Psychiatric Association. Practice Guidelines for the treatment of major depressive disorder. 2010. http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1667485. Accessed 19 June 2014.

  2. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;16(6):1433–42.

    Article  CAS  PubMed Central  Google Scholar 

  3. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.

    Article  PubMed  Google Scholar 

  4. Lundbeck. Brintellix™ (vortioxetine hydrobromide tablets): US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf. Accessed 20 June 2014.

  5. Lundbeck. Brintellix™ (vortioxetine tablets): EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf. Accessed 20 June 2014.

  6. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206–21.

    Article  CAS  PubMed  Google Scholar 

  7. Areberg J, Luntang-Jensen M, Søgaard B, et al. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol. 2012;110(4):401–4.

    Article  CAS  PubMed  Google Scholar 

  8. Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013;23(10):1190–8.

    Article  CAS  PubMed  Google Scholar 

  9. Sánchez C, Pehrson AL, Bétry C, et al. Vortioxetine (LU aa21004), an investigational multimodal antidepressant: differentiation from currently used antidepressants in preclinical rodent models [abstract]. Biol Psychiatry. 2013;9(Suppl. 1):106S–7S.

    Google Scholar 

  10. Sánchez C. Lu AA21004, a novel multimodal antidepressant. Neurotherapeutics. 2012;9(3):681–2.

    Google Scholar 

  11. Li Y, Pehrson AL, Budac DP, et al. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. Behav Brain Res. 2012;234(2):238–47.

    Article  CAS  PubMed  Google Scholar 

  12. Wilson S, Buchbjerg J, Højer AM, et al. Effects of vortioxetine versus paroxetine on polysomnography in man: a pharmacokinetic/pharmacodynamic study [abstract no. P.1.g.013]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S195–6.

    Article  Google Scholar 

  13. Wang Y, Nomikos GG, Karim A, et al. Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: results of a thorough QT/QTC study. Clin Pharmacol Drug Dev. 2013;2(4):298–309.

    Google Scholar 

  14. Højer AM, Søgaard B, Areberg J. Investigation of the absorption profile of Lu AA21004 [abstract no. P 27]. Int J Psychiatry Clin Pract. 2011;15:25.

    Google Scholar 

  15. Pehrson AL, Cremers T, Bétry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013;23(2):133–45.

    Article  CAS  PubMed  Google Scholar 

  16. Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666–75.

    Article  PubMed  Google Scholar 

  17. Mørk A, Brennum L, Fallon S, et al. Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders [abstract no. P.2.d.017]. Eur Neuropsychopharmacol. 2009;19:S439.

    Article  Google Scholar 

  18. Mørk A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013;105:41–50.

    Article  PubMed  Google Scholar 

  19. Du Jardin KG, Liebenberg N, Muller H, et al. Single dose vortioxetine or ketamine but not fluoxetine increases expression of neuroplasticity related genes in the rat prefrontal cortex [abstract no. P.2.e.001]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S392.

    Article  Google Scholar 

  20. Pehrson A, Li Y, Haddjeri N, et al. Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms [abstract no. P.1.g.014]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S196–7.

    Article  Google Scholar 

  21. Riga MS, Celada P, Sanchez C, et al. Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine [abstract no. P.2.e.003]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S393–4.

    Article  Google Scholar 

  22. Dale E, Zhang H, Leiser SC, et al. Vortioxetine (Lu AA21004) disinhibits pyramidal cell output and enhances theta rhythms and long-term plasticity in the hippocampus [abstract no. P.2.e.004]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S394.

    Article  Google Scholar 

  23. Bétry C, Pehrson AL, Etiévant A, et al. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Int J Neuropsychopharmacol. 2013;16(5):1115–27.

    Article  PubMed  Google Scholar 

  24. Guilloux J-P, Mendez-David I, Pehrson A, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013;73:147–59.

    Article  CAS  PubMed  Google Scholar 

  25. Haddjeri N, Etievant A, Pehrson A, et al. Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition [abstract no. P.2.h.002]. Eur Neuropsychopharmacol. 2012;22(Suppl. 2):S303.

    Article  Google Scholar 

  26. Leiser SC, Pehrson AL, Robichaud PJ, et al. Preclinical studies of the multimodal antidepressant vortioxetine support a potential for improvement of cognitive functions [abstract no. M157]. Neuropsychopharmacology. 2012;38:S164–5.

    Google Scholar 

  27. du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2014;24(1):160–71.

    Article  PubMed  Google Scholar 

  28. Pehrson A, Plath N, Sanchez C. Vortioxetine (LU AA21004), an investigational multimodal antidepressant, reverses executive function deficits in rats treated subchronically with PCP [abstract no. NR11-56]. In: 166th annual meeting of the American Psychiatric Association; 18–22 May 2013; San Francisco.

  29. Theunissen EL, Street D, Højer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013;93(6):493–501.

    Article  CAS  PubMed  Google Scholar 

  30. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–23.

    Article  PubMed  Google Scholar 

  31. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014. doi:10.1017/S1461145714000546.

    PubMed  Google Scholar 

  32. Mahableshwarkar A, Zajecka J, Jacobson W, et al. Efficacy of vortioxetine on cognitive function in adult patients with major depressive disorder: results of a randomized, double-blind, active-referenced, placebo-controlled trial [abstract no. 016]. In: 29th CINP World Congress of Neuropsychopharmacology; 22–26 June 2014; Vancouver.

  33. Areberg J, Sogaard B, Hojer A-M. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol. 2012;111(3):198–205.

    CAS  PubMed  Google Scholar 

  34. Mayer M, Xie J, Serenko M. Effect of formulation and food on the pharmacokinetics of Lu AA21004 in healthy subjects [abstract no. PII-49]. Clin Pharmacol Ther. 2012;91:S69–70.

    Google Scholar 

  35. Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012;40(7):1357–65.

    Article  CAS  PubMed  Google Scholar 

  36. Dudkowski C, Lee R, Wu R, et al. A phase 1 study to assess the effect of age, gender and race on the pharmacokinetics of single and multiple doses of Lu AA21004 in healthy subjects [abstract no. PII-48]. Clin Pharmacol Ther. 2012;91:S69.

    Google Scholar 

  37. Wang Y, Munsaka M, Serenko M, et al. Evaluation of the single-dose pharmacokinetics of Lu AA21004 and its metabolites in subjects with and without hepatic impairment [abstract no. PIII-13]. Clin Pharmacol Ther. 2011;89(Suppl. 1):S71.

    Google Scholar 

  38. Chen G, Lee R, Hojer A-M, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727–36.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Chen G, Lee R, Zhao Z, et al. A Phase 1 study to assess the effect of LU AA21004 on the steady-state pharmacokinetics of lithium in healthy male subjects [abstract no. PI-84]. Clin Pharmacol Ther. 2012;91:S39.

    Article  Google Scholar 

  40. Lee RD, Wang Y, Zhao Z, et al. Effects of multiple doses of Lu AA21004 on the steady-state pharmacokinetics and pharmacodynamics of warfarin [abstract no. 1122787]. J Clin Pharmacol. 2011;51(9):1346.

    Google Scholar 

  41. Chen G, Wang Y, Lee RD, et al. Effects of multiple doses of Lu AA21004 on the single-dose pharmacokinetics and pharmacodynamics of diazepam [abstract no. 1123287]. J Clin Pharmacol. 2011;51(9):1350.

    Google Scholar 

  42. Naik H, Chan S, Vakilynejad M, et al. A population pharmacokinetic (pk)-pharmacodynamic (pd) meta-analysis of vortioxetine (Lu AA21004) in patients with major depressive disorder (MDD) [abstract no. NR9-03 plus poster]. In: 166th Annual Meeting of the American Psychological Association; 18–22 May 2013; San Francisco.

  43. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589–600.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Takeda. Efficacy and safety study of vortioxetine (Lu AA21004) for treatment of major depressive disorder [ClinicalTrials.gov identifier NCT 01255787]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 June 2014.

  45. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482–91.

    Article  CAS  PubMed  Google Scholar 

  46. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138–49.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953–9.

    Article  CAS  PubMed  Google Scholar 

  48. Jacobsen P, Mahableshwarkar AR, Serenko M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 and 20 mg in adults with major depressive disorder [abstract no. NR9-06]. In: 166th Annual Meeting of the American Psychiatric Association; 18–22 May 2013; San Francisco.

  49. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313–21.

    Article  CAS  PubMed  Google Scholar 

  50. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217–26.

    Article  CAS  PubMed  Google Scholar 

  51. Mahableshwarkar A, Jacobsen PL, Serenko M. A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD [abstract no. NR9-01]. In: 166th Annual Meeting of the American Psychiatric Association; 18–22 May 2013; San Francisco.

  52. Mahableshwarkar A, Jacobsen PL, Serenko M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder [abstract no. NR9-02]. In: 166th Annual Meeting of the American Psychiatric Association; 18–22 May 2013; San Francisco.

  53. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol (Oxf). 2012;26(11):1408–16.

    Article  Google Scholar 

  54. Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenalin reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014. doi:10.1002/hup.2424.

    Google Scholar 

  55. Takeda. Safety and efficacy study of Lu AA21004 in adults with major depressive disorder [ClinicalTrials.gov identifier NCT01179516]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 June 2014.

  56. Takeda. Efficacy and safety study of Lu AA21004 in adults with major depressive disorder [ClinicalTrials.gov identifier NCT01163266]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 June 2014.

  57. Takeda. Safety and efficacy of vortioxetine (Lu AA21004) in adults with major depressive disorder [ClinicalTrials.gov identifier NCT01153009]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 June 2014.

  58. Lundbeck H. Randomised placebo-controlled duloxetine-referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder [ClinicalTrials.gov identifier NCT00635219]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 30 June 2014.

  59. Lundbeck H. Randomised placebo-controlled duloxetine-referenced study of efficacy and safety of 15 and 20 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults [ClinicalTrials.gov identifier NCT01140906]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 30 June 2014.

  60. Takeda. Efficacy study of vortioxetine (Lu AA21004) in adults with major depressive disorder [ClinicalTrials.gov identifier NCT00735709]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 7 July 2014.

  61. Florea I, Danchenko N, Loft H, et al. The effect of vortioxetine (LU AA21004) on health-related quality of life (HRQOL) in patients with major depressive disorder (MDD) [abstract no. PMH55]. Value Health. 2013;16(3):A65.

    Article  Google Scholar 

  62. Thase ME, Mahableshwarkar A, Dragheim M. The efficacy of vortioxetine vs. placebo in the treatment of adults with major depressive disorder: patient level data from 10 short-term studies and a meta-analysis [abstract no. T142]. Neuropsychopharmacology. 2013;38:S363–4.

    Google Scholar 

  63. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(1):60–82.

    Article  CAS  PubMed  Google Scholar 

  64. Wang G, Gislum M, Filippov G. Randomised, double-blind study of vortioxetine versus venlafaxine in adults with major depressive disorder (MDD) [abstract no. 033]. In: 29th CINP World Congress of Neuropsychopharmacology; 22–26 June 2014; Vancouver.

  65. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012;28(10):1717–24.

    Article  CAS  PubMed  Google Scholar 

  66. Filippov G, Christens PF. Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder [abstract no. P.2.b.011]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S325.

    Article  Google Scholar 

  67. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2013;29(1):36–44.

    Article  Google Scholar 

  68. Jacobsen P, Harper L, Serenko M, et al. A phase 3, long-term, open-label extension study evaluating the safety and tolerability of 15 and 20 mg vortioxetine in subjects with major depressive disorder [abstract no. 017]. In: 29th CINP World Congress of Neuropsychopharmacology; 22–26 June 2014; Vancouver.

  69. Florea I, Dragheim M, Loft H. The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder [abstract no. P.2.c.010]. Eur Neuropsychopharmacol. 2012;22(Suppl. 2):S255–6.

    Article  Google Scholar 

  70. Jacobsen P, Mahableshwarkar AR, Chen Y, et al. Randomized, double-blind, head-to-head, flexible-dose study of vortioxetine vs escitalopram in sexual functioning in adults with well controlled major depressive disorder experiencing treatment-emergent sexual dysfunction [abstract no. 018]. In: 29th CINP World Congress of Neuropsychopharmacology; 22–26 June 2014; Vancouver.

  71. European Medicines Agency. Vortioxetine: assessment report for an initial marketing authorisation application. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002717/WC500159447.pdf. Accessed 20 June 2014.

  72. Gaudiano BA, Herbert JD. Methodological issues in clinical trials of antidepressant medications: perspectives from psychotherapy outcome research. Psychother Psychosom. 2005;74(1):17–25.

    Article  PubMed  Google Scholar 

  73. Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract. 2014;68(1):49–59.

    Article  CAS  PubMed  Google Scholar 

  74. Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol. 2014;29(1):64–72.

    Article  CAS  PubMed  Google Scholar 

  75. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012;22(12):858–66.

    Article  CAS  PubMed  Google Scholar 

  76. Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012;22(12):847–57.

    Article  CAS  PubMed  Google Scholar 

  77. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197–207.

    Article  PubMed  Google Scholar 

  78. Servier. Valdoxan (agomelatine tablets): EU summary of product characteristics. 2009. http://valdoxan.com/sites/default/files/Valdoxan%20SPC.pdf. Accessed 20 June 2014.

  79. Whiting D, Cowen PJ. Drug information update: agomelatine. Psychiatr Online. 2013;37:356–8.

    Article  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. K. P. Garnock-Jones is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Karly P. Garnock-Jones

Authors
  1. Karly P. Garnock-Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karly P. Garnock-Jones.

Additional information

The manuscript was reviewed by: F. Artigas, Department of Neurochemistry and Neuropharmacology, Institut d’ Investigacions Biomediques de Barcelona (CSIC), Barcelona, Spain; R. Jain, Department of Psychiatry and Behavioral Sciences, University of Texas, Houston, Texas, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garnock-Jones, K.P. Vortioxetine: A Review of Its Use in Major Depressive Disorder. CNS Drugs 28, 855–874 (2014). https://doi.org/10.1007/s40263-014-0195-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0195-x

Keywords

Search

Navigation